Hints and tips:
...Unlike their big pharma cousins, they were better known for operational and financial acumen than cutting edge science....
...Lex this week opined on three separate pharma outliers praying for rescues from their “lab rats” — as medical researchers sometimes call themselves....
...Auden Mckenzie and Actavis UK increased the price of a 10mg packet by more than 10,000 per cent compared with the original branded version of the drug, the CMA said....
...Pharma investors have grown to ignore such earnings accretion calculations....
...A former Bausch & Lomb executive, the 49-year-old built Allergan through a succession of deals that began in 2013 when the company he ran, then called Actavis, bought Ireland-headquartered Warner Chilcott...
...Actavis to keep prices artificially high....
....; Aurobindo Pharma USA, Inc.; Citron Pharma, LLC; Mayne Pharma (USA), Inc.; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; Actavis Holdco U.S., Inc.; Actavis Pharma, Inc.; Ascend Laboratories, LLC...
...It is the second time in recent months that the CMA has said it would investigate Actavis over pricing....
...Teva could use a similar shot in the arm, after deciding to spend nearly $40bn in cash and shares on Actavis, another generic pharma specialist, in 2015....
...However shares in the $84bn US-listed Irish pharma group were held back by the sharp-off in Teva....
...Worse for Teva, it doubled down on generics by paying roughly $40bn for Allergan’s Actavis unit — just before prices started to crumble and after some investors warned against the deal....
...However, the CMA said that “by charging excessive and unfair pricing” Actavis had broken competition law....
...Drugmakers also came under fire over pricing during the US presidential campaign, partly after Martin Shkreli, the “bad boy” of pharma, increased the price of a life-saving cancer and Aids drug from $13.50...
...The country’s competition authorities alleged generic companies Concordia and Actavis had fixed the UK market for hydrocortisone tablets....
...But Mr Holford said this seemed unlikely: “The inversion story feels tired now that the Treasury has twice thwarted large-cap pharma deals.”...
...That transaction transformed the company, then known as Actavis, from a manufacturer of generic copycat medicines into a branded drugmaker. “Brent is a bold guy,” says one investor....
...“We would expect Big Pharma’s current level of R&D spending to become a luxury that investors no longer tolerate,” wrote a group of McKinsey consultants in 2011....
...Alpharma’s infringement resulted in fines of £1.5m imposed on Actavis, Xellia Pharmaceuticals, and Alpharma, companies which made up the original Alpharma company....
...Last November, drugmaker Actavis clinched a $66bn deal for Allergan, best known for its Botox treatment but whose biggest business was eyecare products (Actavis later rebranded itself as Allergan)....
...Tim Powell, partner at Powell Gilbert, the law firm that represented Actavis, said the UK ruling provided “welcome clarity in a very complex area of the law”....
...The acquisition gives the UK group global rights to a treatment called roflumilast, for chronic obstructive pulmonary disease, and follows the securing of US rights as part of a $600m deal with Actavis in...
...The battle ended with Allergan securing a huge premium from “white knight” bidder Actavis, the generics pharma company, which paid $70.5bn to buy the company in a deal that closed in March....
...Alpharma, Xellia and Actavis were fined a combined £1.5m. The CMA, which has a remit to protect consumers, has other pharmaceutical companies in its crosshairs, as well....
...It is just over a year since Brent Saunders became chief executive of Allergan, then known as Actavis, but he has changed the company beyond recognition....
...Others include Actavis, which bought Allergan, the maker of Botox, last year for $66bn and has since adopted the Allergan name....
International Edition